{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:00:05Z","timestamp":1772726405166,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-06086-2","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T20:46:38Z","timestamp":1762807598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comment on: \u201cIntravesical administration of highly concentrated hyaluronic acid and chondroitin sulphate as add\u2011on therapy for chemical cystitis induced by Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy\u201d"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-5771","authenticated-orcid":false,"given":"Murat","family":"Akand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozcan","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"6086_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1471-2490-14-64","volume":"14","author":"L Topazio","year":"2014","unstructured":"Topazio L, Miano R, Maurelli V, Gaziev G, Gacci M, Iacovelli V et al (2014) Could hyaluronic acid (HA) reduce Bacillus Calmette-Gu\u00e9rin (BCG) local side effects? Results of a pilot study. BMC Urol 14:64. https:\/\/doi.org\/10.1186\/1471-2490-14-64","journal-title":"BMC Urol"},{"key":"6086_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/UA.UA_115_17","volume":"9","author":"MM Alhogbani","year":"2017","unstructured":"Alhogbani MM, Picard JA, Fassi-Fehri MH, Badet JL, Colombel CM (2017) Prognostic impact of Bacillus Calmette-Gu\u00e9rin interruption at the time of induction and consolidation. Urol Ann 9:315\u2013320. https:\/\/doi.org\/10.4103\/UA.UA_115_17","journal-title":"Urol Ann"},{"key":"6086_CR3","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s11255-025-04375-8","volume":"57","author":"M Gubbiotti","year":"2025","unstructured":"Gubbiotti M, Rubilotta E, Bacchiani M, Cocci A, Rosadi S, Serni S et al (2025) Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy. Int Urol Nephrol 57:2033\u20132039. https:\/\/doi.org\/10.1007\/s11255-025-04375-8","journal-title":"Int Urol Nephrol"},{"key":"6086_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4081\/aiua.2018.1.11","volume":"90","author":"V Imperatore","year":"2018","unstructured":"Imperatore V, Creta M, Di Meo S, Buonopane R, Longo N, Fusco F et al (2018) Intravesical administration of combined hyaluronic acid and chondroitin sulfate can improve symptoms in patients with refractory Bacillus Calmette-Guerin-induced chemical cystitis: preliminary experience with one-year follow-up. Arch Ital Urol Androl 90:11\u201314. https:\/\/doi.org\/10.4081\/aiua.2018.1.11","journal-title":"Arch Ital Urol Androl"},{"key":"6086_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F et al (2024) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update. Eur Urol 86:531\u2013549. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027","journal-title":"Eur Urol"},{"key":"6086_CR6","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.3390\/cancers\/16213653","volume":"16","author":"M Akand","year":"2024","unstructured":"Akand M, Veys R, Ost D, Vander Eeckt K, Baekelandt F, Van Reusel R et al (2024) Cohort profile: VZNKUL\u2014NMIBC quality indicators program: a Flemish prospective cohort to evaluate the quality indicators in the treatment of non-muscle-invasive bladder cancer. Cancers 16:3653. https:\/\/doi.org\/10.3390\/cancers\/16213653","journal-title":"Cancers"},{"key":"6086_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/CAD.0000000000000775","volume":"30","author":"S Poletajew","year":"2019","unstructured":"Poletajew S, Krajewski W, Adamowicz J, Radziszewski P (2019) A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical Bacillus Calmette\u2013Gu\u00e9rin immunotherapy. Anticancer Drugs 30:517\u2013522. https:\/\/doi.org\/10.1097\/CAD.0000000000000775","journal-title":"Anticancer Drugs"},{"key":"6086_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC et al (2024) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guidelines: 2024 amendment. J Urol 211:533\u2013538. https:\/\/doi.org\/10.1097\/JU.0000000000003846","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-06086-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:03:34Z","timestamp":1767999814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-06086-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6086"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-06086-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"686"}}